The Safety and Biological Activity of OTT166, a Novel Topical Selective Integrin Inhibitor for the Treatment of Diabetic Eye Disease : A Phase 1b Study
BACKGROUND AND OBJECTIVES: To evaluate the safety, tolerability, and biological activity of a topical selective integrin inhibitor (OTT166) eyedrop administered BID for diabetic retinopathy (DR) and diabetic macular edema (DME)
Détails bibliographiques
| Publié dans: | Ophthalmic surgery, lasers & imaging retina. - 2013. - 53(2022), 10 vom: 17. Okt., Seite 553-560
|
|---|
| Auteur principal: |
Boyer, David S
(Auteur) |
|---|
| Autres auteurs: |
Kaiser, Peter K,
Magrath, George N,
Brady, Kerrie,
Edwards, Scott,
Tanzer, David J,
Heier, Jeffrey S |
|---|
| Format: | Article en ligne
|
|---|
| Langue: | English |
|---|
| Publié: |
2022
|
|---|
| Accès à la collection: | Ophthalmic surgery, lasers & imaging retina
|
|---|
| Sujets: | Clinical Trial, Phase I
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Integrins
Ophthalmic Solutions |
|---|